Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma.

ABSTRACT:

Background

Systemic treatment of soft-tissue sarcoma (STS) relies on cytotoxic chemotherapy, with doxorubicin being the key therapeutic agent. However, immune activation is required for optimal antitumor effects of doxorubicin. This study investigated whether activation of the STING pathway enhances doxorubicin's antitumor effect in STS.

Methods

STS cell lines were treated with doxorubicin to evaluate the activation of STING pathway. Deletion of Sting1 gene was employed to validate its role in mediating doxorubicin's effects. In a syngeneic mouse model of STS, doxorubicin was administered alone or in combination with a STING agonist ADU-S100. Tumor-infiltrating CD45⁺ cells were magnetically sorted for RNA sequencing to identify genes and pathways linked to

SUBMITTER: Choi W 

PROVIDER: S-EPMC12740912 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature